Electronic cigarettes as a harm reduction strategy in people living with HIV/AIDS

Brief description of study

People living with HIV/AIDS (PLWHA) are known to have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. Although a primary rationale for conducting this study is reducing health disparities among PLWHA, there is a potential benefit of the proposed work from a prevention perspective given that combustible cigarette smoking is an independent risk factor for non-adherence to ART and may decrease the effectiveness of HAART (1-5). Smoking-related illnesses are leading causes of non-HIV/AIDS-related deaths among People Living with HIV/AIDS (PLWHA). (6) There are major yet unique barriers to combustible cigarette (CC) cessation among PLWHA.7? Additionally, FDA approved CC cessation medications have not been effective with this population. (8-11) Electronic cigarettes (E-cigarettes) could help people reduce the harm of CC through reductions in number of Cigarettes per Day (CPD) or quitting CC completely by addressing both nicotine and behavioral dependence. (12-14) A harm reduction approach may be more appropriate to use with PLWHA.15 This mixed-methods study’s purpose is to identify barriers and facilitators, as well as assess preliminary effectiveness of e-cigarettes as a harm reduction strategy among PLWHA.


Clinical Study Identifier: s19-01179
ClinicalTrials.gov Identifier: NCT04218708
Principal Investigator: Omar El Shahawy.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.